122 related articles for article (PubMed ID: 6423840)
1. Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate.
Paulson DF; Hodge GB; Hinshaw W
J Urol; 1984 May; 131(5):901-2. PubMed ID: 6423840
[TBL] [Abstract][Full Text] [Related]
2. Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma.
Paulson DF; Cline WA; Koefoot RB; Hinshaw W; Stephani S
J Urol; 1982 May; 127(5):935-7. PubMed ID: 6806486
[TBL] [Abstract][Full Text] [Related]
3. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
Lawton CA; Winter K; Grignon D; Pilepich MV
J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
[TBL] [Abstract][Full Text] [Related]
4. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression.
Zincke H; Utz DC; Taylor WF
J Urol; 1986 Jun; 135(6):1199-205. PubMed ID: 3086572
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.
Zagars GK; Johnson DE; von Eschenbach AC; Hussey DH
Int J Radiat Oncol Biol Phys; 1988 Jun; 14(6):1085-91. PubMed ID: 3133327
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of the prostate: the therapeutic dilemma.
Paulson DF
Annu Rev Med; 1984; 35():341-72. PubMed ID: 6372662
[TBL] [Abstract][Full Text] [Related]
7. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
8. [Prostatic cancer presenting as palpable lymph node metastasis--report of three cases].
Masuda H; Yamada T; Nagahama K; Nagamatsu H; Negishi T
Hinyokika Kiyo; 1992 Nov; 38(11):1269-72. PubMed ID: 1485580
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07.
Pilepich MV; Buzydlowski JW; John MJ; Rubin P; McGowan DG; Marcial VA
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):175-80. PubMed ID: 7721614
[TBL] [Abstract][Full Text] [Related]
10. Prostate Carcinoma-therapeutic considerations in the management of gross lymph node metastases.
Green N; Broth E; George FW; Goldstein A; Melbye RW; Morrow J; Onofrio R; Polse S; Skaist L
Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):891-7. PubMed ID: 115816
[No Abstract] [Full Text] [Related]
11. Carcinoma of the prostate: treatment with external radiotherapy.
Harisiadis L; Veenema RJ; Senyszyn JJ; Puchner PJ; Tretter P; Romas NA; Chang CH; Lattimer JK; Tannenbaum M
Cancer; 1978 Jun; 41(6):2131-42. PubMed ID: 657085
[No Abstract] [Full Text] [Related]
12. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
Spratt DE; Vargas HA; Zumsteg ZS; Golia Pernicka JS; Osborne JR; Pei X; Zelefsky MJ
Eur Urol; 2017 Jan; 71(1):37-43. PubMed ID: 27523595
[TBL] [Abstract][Full Text] [Related]
14. Radical excision of adenocarcinoma of prostate with pelvic lymph node involvement: surgical gesture or curative procedure.
Utz DC
Urology; 1984 Nov; 24(5 Suppl):4-11. PubMed ID: 6495469
[TBL] [Abstract][Full Text] [Related]
15. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
16. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
[TBL] [Abstract][Full Text] [Related]
17. An unusual remission of prostatic carcinoma with pulmonary metastases.
Stenberg CC; Bunts RC
J Urol; 1969 Aug; 102(2):236-9. PubMed ID: 5796902
[No Abstract] [Full Text] [Related]
18. Megavoltage radiation therapy for carcinoma of the prostate.
Neglia WJ; Hussey DH; Johnson DE
Int J Radiat Oncol Biol Phys; 1977; 2(9-10):873-83. PubMed ID: 412817
[No Abstract] [Full Text] [Related]
19. Pelvic lymphadenectomy as staging before definitive treatment of prostatic carcinoma.
Elfving P; Lundgren R
Scand J Urol Nephrol Suppl; 1988; 110():155-61. PubMed ID: 3142034
[TBL] [Abstract][Full Text] [Related]
20. Implications of volume of nodal metastasis in patients with adenocarcinoma of the prostate.
Smith JA; Middleton RG
J Urol; 1985 Apr; 133(4):617-9. PubMed ID: 3920406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
